Experiencing SightGlass Vision’s Spectacle Lenses - reviewofmm.com/initial-clini…

Excited to share this article from @PCONews about the growing #myopia epidemic and how our novel DOT spectacle lenses are designed to slow #myopia progression in children. bit.ly/2DiAdjR

Check out this article @MassDevice about achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow #myopia progression in children. bit.ly/3fCl3nt

Thank you Review of #Myopia Management for this article about our CE Mark achievement for our novel DOT spectacles lenses for myopia management in children. bit.ly/37JHnIZ

Check out this @EyewireTV segment about our suite of novel DOT spectacle lenses designed to slow #myopia progress in children and achieving CE Mark allowing European Marketing Authorization. bit.ly/2N8MWHt

Excited to share this article from #FierceBiotech about achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow #myopia progression in children. bit.ly/3efrSev

Excited to share this WSJ.com article about #myopia that features @SightGlassVis and our novel DOT spectacle lenses. on.wsj.com/30jwRqo

Achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow the progression of #myopia in children is an important leap forward for our Company, as we advance our mission to end #myopia. prn.to/2ADopYo

We now have definitive data to show that our novel eyeglasses reduce the progression of nearsightedness in children. Check out this article in #Eyewire about our #CYPRESS pivotal trial topline data. bit.ly/2LbUSqB

Check out this Optometric Management article about our #CYPRESS pivotal trial in #myopia. Topline 1-yr results showed both test arms met superiority in terms of cycloplegic SER change from baseline and axial length change from baseline.

Excited to share this article from #Healio Primary Care Optometry News about topline data from our #CYPRESS pivotal trial investigating our novel eyeglasses for #myopia in children. bit.ly/35JE1ES

Check out the topline data from our #CYPRESS pivotal trial investigating our novel eyeglasses for #myopia in children. Results showed both test arms met superiority in terms of cycloplegic SER change from baseline and axial length change from baseline. prn.to/3eWLiFK

Thanks to Optical Journal bit.ly/2RqUEiU and Eyewire News bit.ly/34njllF for writing about the positive data from our #CYPRESS pivotal trial investigating our novel spectacle lenses for #myopia in children.

Check out the write up about our #CYPRESS pivotal trial investigating novel eyeglasses for #myopia in children in Review of Myopia Management bit.ly/2UVFjsI.

Excited to share this article from Optometric Management about our #CYPRESS pivotal trial of novel eyeglasses for #myopia in children.

We're excited to announce that a planned interim analysis from our #CYPRESS pivotal clinical trial of novel eyeglasses designed to control #nearsightedness (#myopia) demonstrated successful reduction of myopia progression in children. Click here prn.to/2xG3yC4 for info

Check out Joe Rappon, OD, MS, FAAO, Chief Medical Officer at SightGlass Vision, on camera interview with Helio at the World Congress of Optometry 2019 #myopia healio.com/optometry/pediatr…

#ICYMI: We presented data from our three studies overviewing discovery to clinical development of our novel lenses to control #myopia in children – PALM (pilot), WALNUT (preliminary), CYPRESS (pivotal) – at Academy 2019 & 3rd #WCOCongress19. prn.to/2JhJj0D. #myopia

We look forward to presenting for the first time data that tell the whole story of our novel lenses to control nearsightedness in children – from concept to the clinic – at Academy 2019 & 3rd World Congress of Optometry. prn.to/2JhJj0D. #myopia #Academy19 #WCOCongress19